Overview
- Cofepris approved commercialization this week, enabling purchases at pharmacies, private hospitals and clinics.
- The formulation sold as Comirnaty LP.8.1 is Pfizer’s latest mRNA update intended to reduce the risk of severe COVID-19.
- Use is authorized for three age groups: 6 months to 4 years, 5 to 11 years, and 12 years and older.
- Initial retail listings show prices near 948–949 pesos at San Pablo Farmacia and Farmacia del Ahorro.
- Pfizer México’s Juan Luis Morell highlighted coordination with Health Secretary David Kershenobich and Cofepris chief Armida Zúñiga Estrada to broaden access.